Evenity denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for evenity are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Evenity as Experimental

Evenity (romosozumab) received FDA approval for the treatment of osteoporosis in postmenopausal women at high risk for fracture. An "experimental" or "investigational" denial from Aetna typically occurs when the specific indication for which Evenity is being prescribed falls outside the precise wording of Aetna's clinical policy — for example, when prescribed for a patient population or fracture-risk category that Aetna has not yet incorporated into its coverage criteria — or when the claim is processed under an outdated policy version that predates the FDA approval date.

## Why This Denial Is Appealable

Because Evenity holds full FDA approval for its labeled indication, an experimental denial is among the most reversible denial types. FDA approval is the standard benchmark for "not experimental" under most commercial plan documents. If Aetna's policy has not been updated to reflect the current FDA approval, that is an administrative error subject to correction on internal appeal. You are entitled to a full internal appeal under ERISA §503 or your state's insurance law, and to independent external review under ACA §2719 after internal remedies are exhausted, generally within approximately four months of the final internal denial. Expedited review is available if your clinical situation is urgent.

## Your Appeal Timeline

1. Request the denial letter and Aetna's operative clinical policy for Evenity, including its effective date. 2. Obtain the FDA-approved prescribing label for romosozumab confirming the approved indication. 3. File a first-level internal appeal within the deadline shown on your Explanation of Benefits. 4. Escalate to external review if the internal appeal is denied.

## Documentation to Gather

• FDA approval documentation: A copy of (or citation to) the FDA-approved prescribing label for romosozumab confirming the indication under which it was prescribed.
• Diagnosis confirmation: DXA scan reports, fracture history, and clinical notes establishing that your diagnosis falls within the FDA-approved labeled indication.
• Prescriber medical-necessity letter: A letter from your prescribing physician — typically an endocrinologist, rheumatologist, or primary care provider — affirming that Evenity is being used within its FDA-approved indication and is consistent with current clinical practice guidelines from the relevant professional society (e.g., Endocrine Society or ASBMR).
• Aetna policy effective date: If the policy version Aetna cited predates the FDA approval of romosozumab, note that discrepancy explicitly in your appeal.

## Criteria-Mapping Structure

Review Aetna's clinical policy language defining "experimental/investigational." Then map each element:

| Experimental/Investigational Criterion | Your Rebuttal Evidence | |---|---| | FDA approval status | Cite FDA approval date and labeled indication from prescribing label | | Use matches approved indication | Cite diagnosis code and prescriber letter | | Clinical guideline support | Cite applicable society guideline organization | | Policy version is current | Cite policy effective date vs. FDA approval date |

A concise, factual rebuttal showing FDA approval and on-label use is typically sufficient to overturn an experimental denial for Evenity.